Skip to main content

Scilex Holding Co

SCLX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001820190

No open-market purchases or sales by Scilex Holding Co insiders were filed in the last 90 days; 73 institutions reported holding it in 13F filings for Q2 2026, worth $5.48M in total; no superinvestor holds it.

Other share classesSCLXW

Q3 2025 vs. Q2 2025

How the institutions holding Scilex Holding Co changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of SCLX: Q2 2025 compared with Q3 2025
MeasureQ2 2025Of which not filed for Q3 2025Q3 2025Change
Holders69183+15
Shares635.3K13.6K759.9K+138.3K (+22.3%)
Value$3.72M$80.4K$15.0M+$11.3M (+310.8%)

1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (24)

Institutions that held Scilex Holding Co at the end of Q3 2025 but not at the end of Q2 2025.

Sold out (9)

Institutions that held Scilex Holding Co at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of SCLX in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Rafferty Asset Management, LLC17,718$104.4K
Citadel Advisors LLC12,658$74.6K
B. Riley Financial, Inc.12,414$73.1K
National Bank of Canada1,795$10.4K
Raymond James Financial Inc473$2.79K
Amalgamated Bank3,046$1.00K
Golden State Wealth Management, LLC20$118
Legal & General Group Plc5$29
Asset Dedication, LLC3$18

Not filed for Q3 2025 yet (1)

Institutions that held Scilex Holding Co at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding SCLX in Q2 2025 that haven't filed for Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Norges Bank13,644$80.4K